An Open-Label Phase Followed by a Randomized, Double-Blind, Placebo-Controlled Phase in a Study Designed to Evaluate Intravenous 2-O, 3-O Desulfated Heparin (ODSH) in Subjects With Exacerbations of Chronic Obstructive Pulmonary Disease
Latest Information Update: 11 Nov 2021
Price :
$35 *
At a glance
- Drugs Dociparstat sodium (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Cantex Pharmaceuticals
- 07 Jun 2011 Planned end date changed from 1 Aug 2009 to 1 Oct 2009 as reported by ClinicalTrials.gov.
- 18 Aug 2009 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 18 Aug 2009 Actual patient number (150) added as reported by ClinicalTrials.gov.